An interventional study of high dose chemo then auto hematopoietic cell transplant in Hodgkin Disease, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 4 Weeks to 70 Years. Per ClinicalTrials.gov, last updated 2012-11-12.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
To evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation in the treatment of Hodgkin's Disease.
Use of High Dose Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Relapsed or Resistant Hodgkin's Disease
914 studies on the registry are indexed under Hodgkin Disease; 136 are open to participants now.
This study's enrollment of 200 is above the median of 43 across 746 interventional studies indexed under Hodgkin Disease.
Browse Hodgkin Disease studies →Stanford University is the lead sponsor of 2,161 studies on the registry; 428 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:- adequate organ function
Overall survival
FFS
Response rates
Toxicity of high dose chemotherapy
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.